Filing Details
- Accession Number:
- 0000059478-18-000082
- Form Type:
- 13G Filing
- Publication Date:
- 2018-02-14 13:56:12
- Filed By:
- Lilly Eli & Co
- Company:
- Zosano Pharma Corp (NASDAQ:ZSAN)
- Filing Date:
- 2018-02-14
- SEC Url:
- 13G Filing
Ownership Summary
Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | 1,363,636 | 0 | 1,363,636 | 0 | 1,363,636 | 3.5% |
Filing
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13G/A
Under the Securities Exchange Act of 1934
(Amendment No: 1)*
Zosano Pharma Corporation
(Name of lssuer)
Common Stock; $0.0001 par value
(Title of Class of Securities)
98979H103
(CUSIP Number)
December 31, 2017
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
[ ] Rule 13d-l (b)
[x] Rule 13d-l (c)
[ ] Rule 13d-l (d)
*The remainder of this cover page shall be filled out for a reporting person's initial filing of this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.
1. Name of Reporting Person
Eli Lilly and Company
I.R.S. Identification No. of Above Person (Entities Only)
35-0470950
2. Check the Appropriate Box if a Member of a Group
(a)__(b)__
3. SEC Use Only
4. Citizenship or Place of Organization
Indiana
Number of shares beneficially owned by each reporting person with:
5. Sole Voting Power: 1,363,636
6. Shared Voting Power: 0
7. Sole Dispositive Power: 1,363,636
8. Shared Dispositive Power: 0
9. Aggregate Amount Beneficially Owned by Each Reporting Person
1,363,636
10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares
[ ]
11. Percent of Class Represented by Amount in Row (9)
3.5%
12. Type of Reporting Person
CO
Item l(a) Name of Issuer
Zosano Pharma Corporation
Item l(b) Address of Issuer's Principal Executive Offices
34790 Ardentech Court
Fremont, California 94555
Item 2(a) Name of Person Filing
This Statement is filed on behalf of Eli Lilly and Company, an Indiana corporation.
Item 2(b) Address of Principal Business Office, or if none, Residence
Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285.
Item 2(c) Citizenship
Eli Lilly and Company is an Indiana corporation.
Item 2(d) Title of Class of Securities
Common Stock, par value $0.0001 per share
Item 2(e) CUSIP Number
98979H103
Item 3. Filing pursuant to Rules 13d-l(b) or 13d-2(b) or (c)
Not Applicable
Item 4. Ownership
(a) Amount Beneficially Owned:
1,363,636
(b) Percent of Class:
3.5%
(c) Number of shares as to which the person has:
Sole power to vote or to direct the vote: 1,363,636
Shared power to vote or to direct the vote: 0
Sole power to dispose or to direct the disposition of: 1,363,636
Shared power to dispose or to direct the disposition of: 0
Item 5. Ownership of Five Percent or Less of a Class [X]
Item 6. Ownership of More than Five Percent on Behalf of Another Person
Not Applicable
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security
Being Reported on By the Parent Holding Company
Not Applicable
Item 8. Identification and Classification of Members of the Group
Not Applicable
Item 9. Notice of Dissolution of Group
Not Applicable
Item 10. Certification
By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Date: February 14, 2018
ELI LILLY AND COMPANY
By: /s/ Crystal T. Williams
Name: Crystal T. Williams
Title: Assistant Secretary
This filing is made voluntarily and should not be construed as an admission that the reporting persons are subject to reporting requirements under Section 13 of the Securities Exchange Act of 1934.